💊 SSRI Mechanism & Onset-of-Action Simulator

Fast Pharmacology: SERT Is Blocked Almost Immediately

Placeholder: SERT blockade is fast; feeling better is not.

• Hours: SERT blockade onset (placeholder timing)
• Rapid: Synaptic 5-HT rise (placeholder curve)
• ~0%: Felt relief so far (placeholder gap)
• ~1 day: Drug half-life (placeholder, agent-dependent)

What actually happens on day one

Placeholder: transporter blocked, serotonin climbs, mood unchanged yet.

Why this is only the first step

Placeholder: occupancy is not the same thing as clinical response.

Placeholder: fast target engagement, slow felt benefit.

The Autoreceptor Brake — Why Early Days Can Feel Worse

Placeholder: 5-HT1A autoreceptors push back against the extra serotonin.

• Inhibitory: Autoreceptor response (placeholder feedback)
• Minimal: Typical felt benefit (placeholder window)
• Possible: Activation-type effects (placeholder side effects)
• ~1–2 wk: Duration of this phase (placeholder estimate)

Negative feedback slows net signaling

Placeholder: raphe firing rate drops, offsetting reuptake blockade.

Why patients may feel more anxious first

Placeholder: early activation syndrome, not a sign of failure.

Placeholder: worse-before-better is pharmacologically expected here.

The Brake Releases — Autoreceptors Desensitize

Placeholder: over weeks, inhibitory autoreceptors lose sensitivity.

• 2–4 wk: Desensitization window (placeholder estimate)
• Rising: Net serotonergic tone (placeholder trend)
• Emerging: Clinical signal (placeholder, partial)
• Receptor adaptation: Mechanism type (placeholder label)

From braked to disinhibited signaling

Placeholder: firing rate normalizes, forebrain serotonin output climbs.

First hints of symptom change

Placeholder: small, inconsistent improvement often starts here.

Placeholder: this is the pivot point of the whole delay.

Downstream Neuroplasticity Accumulates

Placeholder: BDNF signaling and synaptic remodeling build up.

• Upregulated: BDNF/TrkB signaling (placeholder pathway)
• Weeks-long: Dendritic remodeling (placeholder timescale)
• Gene transcription: Requires (placeholder mechanism)
• Accelerating: Improvement trend (placeholder trajectory)

Structural change, not just chemistry

Placeholder: spine growth and synaptogenesis take real time.

Why this cannot be rushed

Placeholder: protein synthesis and rewiring are inherently slow.

Placeholder: this is the biological floor on how fast SSRIs can work.

Why Staying the Course Through the Gap Matters

Placeholder: benefit lands around week 4–6 if treatment continues.

• Wk 4–6: Typical benefit onset (placeholder window)
• Benefit stalls: Risk if stopped early (placeholder outcome)
• 4–6 wk: Recommended trial length (placeholder guidance)
• Common: Premature stop rate (placeholder note)

What continuing through the gap buys

Placeholder: adherence lets desensitization and plasticity finish.

What stopping early costs

Placeholder: the model above resets before benefit consolidates.

Placeholder: the gap is expected, not evidence the drug failed.